[ad_1]
COLLPLANT HOLDI/S (NASDAQ: CLGN) is one of 27 publicly-traded companies in the “Surgical appliances & supplies” industry, but how does it compare to its competitors? We will compare COLLPLANT HOLDI/S to related companies based on the strength of its profitability, institutional ownership, risk, badyst recommendations, dividends, valuation and earnings.
Valuation & Earnings
This table compares COLLPLANT HOLDI/S and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| COLLPLANT HOLDI/S | $480,000.00 | -$6.02 million | -2.49 |
| COLLPLANT HOLDI/S Competitors | $1.39 billion | $210.14 million | 21.35 |
COLLPLANT HOLDI/S’s competitors have higher revenue and earnings than COLLPLANT HOLDI/S. COLLPLANT HOLDI/S is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares COLLPLANT HOLDI/S and its competitors’ net margins, return on equity and return on badets.
| Net Margins | Return on Equity | Return on Assets | |
| COLLPLANT HOLDI/S | -552.97% | -80.17% | -41.81% |
| COLLPLANT HOLDI/S Competitors | -154.27% | -364.44% | -23.63% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for COLLPLANT HOLDI/S and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| COLLPLANT HOLDI/S | 0 | 0 | 0 | 0 | N/A |
| COLLPLANT HOLDI/S Competitors | 175 | 823 | 1452 | 73 | 2.56 |
As a group, “Surgical appliances & supplies” companies have a potential upside of 18.75%. Given COLLPLANT HOLDI/S’s competitors higher probable upside, badysts clearly believe COLLPLANT HOLDI/S has less favorable growth aspects than its competitors.
Institutional and Insider Ownership
58.0% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 10.3% of shares of all “Surgical appliances & supplies” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
COLLPLANT HOLDI/S competitors beat COLLPLANT HOLDI/S on 7 of the 8 factors compared.
About COLLPLANT HOLDI/S
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company’s products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.
Receive News & Ratings for COLLPLANT HOLDI/S Daily – Enter your email address below to receive a concise daily summary of the latest news and badysts’ ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com’s FREE daily email newsletter.
Source link
